New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.);  ; medroxyprogesterone acetate 2.6mg (includes 4% overage.); conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.); medroxyprogesterone acetate 2.6mg (includes 4% overage.) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.)   medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose   opacode black s-8-27741 povidone shellac stearic acid sucrose     titanium dioxide   active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.) medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide  

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.);  ; medroxyprogesterone acetate 5mg (includes 4% overage); conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.); medroxyprogesterone acetate 5mg (includes 4% overage) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.)   medroxyprogesterone acetate 5mg (includes 4% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogols magnesium stearate methylcellulose microcrystalline cellulose   opacode black s-8-27741 povidone shellac stearic acid sucrose     titanium dioxide   active: conjugated estrogens 0.625mg (15mg as a dessication with lactose. includes 3% overage.) medroxyprogesterone acetate 5mg (includes 4% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate indigo carmine lactose monohydrate macrogols magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide  

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - aluminium hydroxide; quil-a; recombinant gp70 sub-type a - misc. vaccines or anti sera - aluminium hydroxide mineral-aluminium-base active 3.0 mg/do; quil-a plant active 10.0 ug/do; recombinant gp70 sub-type a vaccine-antigen/antibody active 102.0 ug/do - immunotherapy - cat | cat - queen | cat - tom | kitten - feline leukaemia virus | disease caused by

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - amphotericin b; neomycin; polymixin b; feline leukaemia virus - inactivated; thiomersal - misc. vaccines or anti sera - amphotericin b antibiotic active 0.0 undefined; neomycin antibiotic active 0.0 undefined; polymixin b antibiotic active 0.0 undefined; feline leukaemia virus - inactivated vaccine-viral active 0.0 undefined; thiomersal mercury other 0.0 undefined - immunotherapy - cat | cat - queen | cat - tom | kitten - feline leukaemia virus | disease caused by

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - quil; aluminium hydroxide; recombinant gp70 sub-type a - parenteral liquid/solution/suspension - quil ungrouped active 10.0 ug/do; aluminium hydroxide mineral-aluminium-base active 3.0 mg/do; recombinant gp70 sub-type a vaccine-antigen/antibody active 102.0 ug/do - immunotherapy - cat | cat - queen | cat - tom | kitten - feline leukaemia virus | vaccine | disease caused by | equine rotavirus

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus - cats - for active immunisation of cats from eight weeks of age against:feline calicivirosis to reduce clinical signs.feline viral rhinotracheitis to reduce clinical signs and viral excretion.feline panleucopenia to prevent leucopenia and to reduce clinical signs.feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.duration of immunity: one year after the primary vaccination for all components.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), graphite (unii: 4qqn74lh4o) (graphite - unii:4qqn74lh4o), iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4), iris versicolor - epinephrine 15 [hp_x] in 1 ml - hypoglycemia  formulated for symptoms associated with blood sugar imbalance such as anxiety, trembling, palpitations, fatigue, irritability, headache and cravings. formulated for symptoms associated with blood sugar imbalance such as anxiety, trembling, palpitations, fatigue, irritability, headache and cravings.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), graphite (unii: 4qqn74lh4o) (graphite - unii:4qqn74lh4o), iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4), iris versicolor - epinephrine 15 [hp_x] in 1 g - hypoglycemia  formulated for symptoms associated with blood sugar imbalance such as anxiety, trembling, palpitations, fatigue, irritability, headache and cravings. formulated for symptoms associated with blood sugar imbalance such as anxiety, trembling, palpitations, fatigue, irritability, headache and cravings.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - memantine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate; oestrogens - conjugated -